Loading…
Glaukos Corporation is projected to rise to $228.58 by 2027, a +36% move from its current price of $168.52. GKOS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $164.86 | $168.67 | $172.57 | +0.09% |
| Aug 2 | $163.46 | $168.82 | $174.37 | +0.18% |
| Aug 3 | $162.42 | $168.98 | $175.80 | +0.27% |
| Aug 4 | $161.58 | $169.13 | $177.04 | +0.36% |
| Aug 5 | $160.85 | $169.28 | $178.15 | +0.45% |
| Aug 6 | $160.21 | $169.43 | $179.19 | +0.54% |
| Aug 7 | $159.64 | $169.59 | $180.15 | +0.63% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $159.64 | $169.59 | $180.15 | +0.63% |
| Week 2 | $156.68 | $170.66 | $185.89 | +1.27% |
| Week 3 | $154.67 | $171.74 | $190.69 | +1.91% |
| Week 4 | $153.15 | $172.83 | $195.03 | +2.56% |
| Week 5 | $151.94 | $173.92 | $199.09 | +3.21% |
| Week 6 | $150.94 | $175.02 | $202.95 | +3.86% |
| Week 7 | $150.10 | $176.13 | $206.67 | +4.52% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Its portfolio includes iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc.
Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corporation (GKOS) is a healthcare company focused on ophthalmic therapies and medical devices. It operates with a niche portfolio of glaucoma, corneal, and retinal disease solutions and distributes through direct sales channels and distributors. GKOS is currently priced at $168.52 per share, with a market capitalization of $9.94B and a rank of 857.
Technical indicators point to a bullish near-term stance, supported by a 14-day RSI of 70, with moving averages at SMA50 $137.66 and SMA200 $116.81. Key levels include support at $127.41 and resistance at $168.52, with a 30-day price range of $144.96 to $195.91.
Forecasts project a rising price trajectory over the coming years, starting with a 2026 avg of $168.52 and extending to 2050 with a long-run average of $3,401.42, accompanied by progressively higher ROIs and bullish sentiment in later years.
A major floor 38.8% below — a decisive break under it would weaken the trend.
The nearest floor, 24.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 16.3% above — clearing it would confirm fresh momentum.
Key GKOS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GKOS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $157.40 | Buy | $159.83 | Buy |
| MA 10 | $155.74 | Buy | $156.78 | Buy |
| MA 20 | $154.16 | Buy | $152.56 | Buy |
| MA 50 | $137.66 | Buy | $142.57 | Buy |
| MA 100 | $128.25 | Buy | $132.79 | Buy |
| MA 200 | $116.81 | Buy | $122.61 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 74.66 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 312.37 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 10.54 | Buy |
| Bollinger %B (20,2) | 1.32 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 11.51 | Buy |
| Ultimate (7,14,28) | 80.66 | Sell |
| Momentum (10) | 13.13 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 160.32 | Buy |
| ADX (14) | 29.23 | Buy |
| ATR (14) | 2.92 | Info |
Near-term technical picture remains bullish, with RSI(14) at 70 signaling positive momentum.
The stock is trading near the $168.52 resistance level, with a SMA50 of $137.66 and a SMA200 of $116.81, indicating a positive trajectory relative to longer-term averages.
In the next 30 days, the price has traded within a range of $144.96 to $195.91, and there is near-term support at $127.41 and resistance at $168.52.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $97.02 | $168.52 | $241.90 | 0% | Neutral | |
| $184.99 | $228.58 | $296.87 | +36% | Bullish | |
| $235.44 | $297.75 | $399.34 | +77% | Bullish | |
| $308.20 | $397.28 | $546.40 | +136% | Bullish | |
| $340.64 | $446.50 | $627.24 | +165% | Bullish | |
| $377.66 | $502.59 | $719.23 | +198% | Bullish | |
| $418.37 | $564.66 | $821.61 | +235% | Bullish | |
| $467.11 | $638.80 | $943.61 | +279% | Bullish | |
| $592.69 | $820.67 | $1,229.24 | +387% | Bullish | |
| $677.15 | $948.82 | $1,439.68 | +463% | Bullish | |
| $1,050.96 | $1,553.38 | $2,488.72 | +822% | Bullish | |
| $2,103.07 | $3,401.42 | $5,902.58 | +19.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $97.02 | $168.52 | $196.46 | +0.00% |
| August 2026 | $150.36 | $175.86 | $210.03 | +4.35% |
| September 2026 | $155.34 | $182.96 | $220.99 | +4.04% |
| October 2026 | $155.68 | $184.38 | $224.70 | +0.78% |
| November 2026 | $158.02 | $188.01 | $230.79 | +1.97% |
| December 2026 | $163.87 | $195.79 | $241.90 | +4.13% |
Click any year to see its month-by-month GKOS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GKOS price prediction for 2026 points to an average of $168.52 (low $97.02, high $241.90) — a potential gain of 0% on today's $168.52. A consolidation phase looks the most probable path here.
In 2027, GKOS is projected to trade between $184.99 and $296.87, averaging $228.58 — a potential gain of +36% from today's $168.52. That is up +36% on the projected 2026 average. Momentum favours further upside here.
Glaukos Corporation's 2028 outlook centres on $297.75, within a $235.44 to $399.34 range. That is up +30% on the projected 2027 average. That marks a +77% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, GKOS could reach as high as $546.40, with a base case around $397.28 and support toward $308.20 — roughly +136% from $168.52. Momentum favours further upside here.
Expect GKOS to range from $340.64 to $627.24 through 2030. The $446.50 average target implies a +165% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The GKOS price prediction for 2031 points to an average of $502.59 (low $377.66, high $719.23) — a potential gain of +198% on today's $168.52. Momentum favours further upside here.
In 2032, GKOS is projected to trade between $418.37 and $821.61, averaging $564.66 — a potential gain of +235% from today's $168.52. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Glaukos Corporation's 2033 outlook centres on $638.80, within a $467.11 to $943.61 range. That is up +13% on the projected 2032 average. That marks a +279% change versus current levels. Momentum favours further upside here.
By 2034, GKOS could reach as high as $1,229.24, with a base case around $820.67 and support toward $592.69 — roughly +387% from $168.52. Buyers look set to stay in control over this stretch.
Expect GKOS to range from $677.15 to $1,439.68 through 2035. The $948.82 average target implies a +463% move from current prices. That is up +16% on the projected 2034 average. Momentum favours further upside here.
The GKOS price prediction for 2040 points to an average of $1,553.38 (low $1,050.96, high $2,488.72) — a potential gain of +822% on today's $168.52. Buyers look set to stay in control over this stretch.
In 2050, GKOS is projected to trade between $2,103.07 and $5,902.58, averaging $3,401.42 — a potential gain of +19.2x from today's $168.52. That is up +119% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GKOS today (≈ 5.934014 GKOS) could be worth
$20,184.04
+$19,184.04 (+1918%) by 2050 · US Dollar
Based on the average projected GKOS price of $3,401.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GKOSwould be worth at today's price.
$1,000 invested in GKOS on Jul 30, 2025 (≈ 10.632642 GKOS) would be worth
$1,791.81
+$791.81 (+79.2%) today · 1.79× · US Dollar
Based on a GKOS entry price of $94.05 vs. today's $168.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $152.13 | $1,107.74 | +10.8% |
| 1 month ago | $139.76 | $1,205.78 | +20.6% |
| 3 months ago | $140.22 | $1,201.83 | +20.2% |
| 6 months ago | $119.38 | $1,411.63 | +41.2% |
| 1 year ago | $94.05 | $1,791.81 | +79.2% |
| All time (5.0y) ago | $51.01 | $3,303.67 | +230.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GKOS forecast.
Our base-case forecast reaches $340.00 around 2029.
Implied market cap at $340.00: $20.05B
The multi-year forecast shows a bullish trajectory, with clear upside across multiple years. In 2026 the average price is projected to be $168.52 with a neutral sentiment, then rising to $228.58 in 2027 (ROI 35.6%) and $297.75 in 2028 (ROI 76.7%), followed by $397.28 in 2029 (ROI 135.8%) and $446.50 in 2030 (ROI 164.9%).
Continuing, 2031 is $502.59 (ROI 198.2%), 2032 is $564.66 (235.1%), and 2033 is $638.80 (279.1%). The forecast then shows $820.67 in 2034 (387%), $948.82 in 2035 (463%), and by 2040 an average of $1,553.38 (ROI 821.8%). By 2050 the average is projected at $3,401.42 with a ROI of 1918.4% and a bullish sentiment.
These figures are estimates, not guarantees, and actual results may differ. They reflect a modeled path of higher averages and rising ranges over time, with substantial upside indicated by the later-year max values.
Tap a question to reveal the answer.
2030 avg price is $446.50, with a min of $340.64 and a max of $627.24. The forecasted ROI is 164.9% and the sentiment is BULLISH.
Forecasts indicate a bullish trajectory through 2050, with rising averages: 2027 avg $228.58 (ROI 35.6%), 2028 $297.75 (76.7%), 2029 $397.28 (135.8%), 2030 $446.50 (164.9%). These are estimates, not guarantees.
Yes, the forecasted maxima exceed $1,000: 2035 max $1,439.68; 2040 max $2,488.72; 2050 max $5,902.58. These are estimates and not guarantees.
The current price is $168.52.
The 30-day range is $144.96 to $195.91.
Glaukos Corporation Community Discussion
0Share your Glaukos Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.